Sydney 0293771500
Adelaide 0882173900

Michael Cawley

Executive Director

Michael has 20 years of investment banking experience specialising in Equity Capital Markets.

Michael has significant experience in all facets of Equity Capital Markets including placements, rights issues, block trades and initial public offerings.  In recent years he has developed a specialisation in healthcare and biotechnology that has seen him take a leading role in the firm’s involvement in this sector.

Before joining Taylor Collison in late 2006, Michael was an Associate Director within the Corporate Finance division of Austock Securities and prior to this commenced his investment banking career with BBY.  Prior to travelling that ultimately resulted in a move to Sydney

Michael also spent 3 years in the audit division of PricewaterhouseCoopers Perth office. Michael has a Bachelor of Commerce from The University of Western Australia and is a member of The Institute of Chartered Accountants in Australia and New Zealand.  He has also completed the Financial Services Institute of Australia’s Graduate Diploma in Applied Finance and Investment.

Contact: mcawley@taylorcollison.com.au

Michael has significant transaction experience across a range of deal types. Examples include:

  • Led the initial public offering of Telix Pharmaceuticals that raised A$50 million and is acknowledged as the largest raising via an IPO for an Australian biotechnology company since the privatisation of CSL in 1994.
  • Lead Manager and Underwriter for a Placement and Underwritten Rights Issue to raise $4.2 million on behalf of Factor Therapeutics
  • Led a private pre-IPO round to raise $8.5 million on behalf of Telix Pharmaceuticals
  • Lead Manager and Underwriter for a Placement and Underwritten Rights Issue to raise $15.0 million on behalf of Factor Therapeutics
  • Other Lead Manager roles have been performed on behalf of RHS, Atcor Medical (now Cardiex), Neuren Pharmaceuticals and Living Cell Technologies.
  • Was a part of the team that identified Sirtex Medical as an outstanding investment opportunity in 2009 with the shares trading at $2.50. Taylor Collison went on to dominate trading market share for many years as the Company’s shares traded as high as $41.33 (Mkt Cap $2.1 billion) and completed a number of block trades, a buy-back and provided general corporate advice to the Company.

Michael has significant transaction experience across a range of deal types. Examples include:

  • Led the initial public offering of Telix Pharmaceuticals that raised A$50 million and is acknowledged as the largest raising via an IPO for an Australian biotechnology company since the privatisation of CSL in 1994.
  • Lead Manager and Underwriter for a Placement and Underwritten Rights Issue to raise $4.2 million on behalf of Factor Therapeutics
  • Led a private pre-IPO round to raise $8.5 million on behalf of Telix Pharmaceuticals
  • Lead Manager and Underwriter for a Placement and Underwritten Rights Issue to raise $15.0 million on behalf of Factor Therapeutics
  • Other Lead Manager roles have been performed on behalf of RHS, Atcor Medical (now Cardiex), Neuren Pharmaceuticals and Living Cell Technologies.
  • Was a part of the team that identified Sirtex Medical as an outstanding investment opportunity in 2009 with the shares trading at $2.50. Taylor Collison went on to dominate trading market share for many years as the Company’s shares traded as high as $41.33 (Mkt Cap $2.1 billion) and completed a number of block trades, a buy-back and provided general corporate advice to the Company.